Therapeutic | Fibatuzumab |
Target | EPHA3 |
Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS |
Light Chain | DIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | POTELLIGENT Technology;Humaneering Technology |
INN Year Proposed | 2015 |
INN Year Recommended | 2017 |
Companies Involved | Ludwig Institute for Cancer Research, Humanigen, Olivia Newton-John Cancer Research Institute |
Conditions Approved | na |
Conditions Active | Acute myeloid leukaemia, Myelodysplastic syndromes, Myelofibrosis, Glioblastoma |
Conditions Discontinued | na |
Notes | Fibatuzumab and Ifabotuzumab are the same mAb |